A new invited pharmaceutical industry editorial by Dr Nat Hastings, Cellestial’s CEO, has recently been published in IBI by SENGLOBAL LTD.
๐ช๐ต๐ฎ๐ ๐๐ฒ ๐น๐ฒ๐ฎ๐ฟ๐ป๐:
โฆ CNS drug discovery focusses on a relatively limited number of targets
โฆ Traditionally, these targets centre on protection or replacement of neurones
โฆ Conceptual frameworks define drug target selection more than tools
โฆ Limited diversity in drug-development pipelines increases risk when multiple programmes depend on the same biological hypotheses
๐ช๐ต๐ฎ๐ ๐๐ต๐ถ๐ ๐บ๐ฒ๐ฎ๐ป๐ ๐ณ๐ผ๐ฟ ๐๐ฒ๐น๐น๐ฒ๐๐๐ถ๐ฎ๐น:
โฆ Expanding Parkinson’s therapeutics pipelines to include other brain cells such as astrocytes offers a differentiated and complementary approach to disease modification
๐ช๐ต๐ฒ๐ฟ๐ฒ ๐๐ผ ๐ด๐ฒ๐ ๐๐ผ๐๐ฟ ๐ฐ๐ผ๐ฝ๐:
โฆ Read free online, pp40-42: https://issuu.com/senglobal1/docs/ibi_autumn_2026?fr=xKAE9_zMzMw
โฆ Find the latest IBI issue at CPHI Milan on 6-8 October
Special thanks to Natalie Swanser of NS Communications LTD for the collaboration on the illustrations.